Loading…

Gevo, Inc.GEVOCompetitor analysis, valuation and peers

United States · USD·Materials›Chemicals: Specialty
Momentum leader 91
Mkt cap
$421M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$7.53M
20-day average traded
Fwd P/E
24.8×
forward earnings
ROIC−WACC
-13.6 pp
WACC 9.2%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$1.70
1D+3.7%
1W-6.6%
1M+50.4%
3M+12.6%
6M+3.7%
YTD-15.0%
1Y-11.0%
ATR %7.7%
Beta1.22
52w lowhigh42.8% off high

What Gevo does

Employees: 151

Gevo at a glance

Size Gevo (GEVO) is a United States Materials company (Chemicals: Specialty) with a market value of $421M, the 2801st largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.70 on 18 Nov 2026.

Performance Over six months the shares gained 3.7%, against -18.0% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 80.1% over the last twelve months (peer median +8.0%); the operating margin is -10.8% (peer median 4.5%).

Valuation It trades at 24.8× forward earnings against a peer median of 16.5× (2nd most expensive of 8).

Capital Return on invested capital runs 13.6 points below its cost of capital (9.2% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026GEVO 100Peer median 83
Six months, rebased to 100: Gevo against the median of its 20 peers (local-currency closes).

Gevo financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$218M$161M$16.9M$17.2M$1.18M
Revenue growth—+849%-2%+1,364%—
Gross profit$91.8M$48.5M-$16.4M-$17.8M-$20.0M
EBITDA$2.41M$6.46M-$67.6M-$62.8M-$69.6M
Net income-$182M-$33.8M-$78.6M-$66.2M-$98.0M
Free cash flow-$30.8M-$43.5M-$108M-$108M-$128M
Capital expenditure$62.8M$30.1M$51.1M$54.5M$75.8M
Total debt$171M$168M$70.6M$70.2M$69.7M

Quarterly statements and history in the cockpit →

Gevo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%+40%ELLENBAK3001324097300927603725603192TATVA00266617103002391313006650001367603798000698301518000707VISHNUGEVO6-month return →1-month return →
Up and to the right = strong over both horizons. Gevo is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×20×40×ELLENBAK300132TATVA1710006650VISHNUGEVORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gevo is the large dot.

Gevo competitors and peer comparison

How Gevo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gevo against its 20 peers (data as of 18 Nov 2026)
MeasureGEVOPeer medianRank in peer set
1-month return+50.4%-10.3%highest of 21
6-month return+3.7%-18.0%5th highest of 21
Distance from 52-week high-42.8%-37.9%9th lowest of 21
Revenue growth (TTM)+80.1%+8.0%2nd highest of 21
Operating margin-10.8%4.5%lowest of 21
Forward P/E24.8×16.5×2nd most expensive of 8
ROIC minus cost of capital-13.6 pp-2.2 pplowest of 21
Net debt / EBITDA43.0×1.8×most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Gevo GEVOUnited States$421M+4%+80%-11%24.8×n/an/a
Ellenbarrie Industrial Gases ELLEN.NSIndia$420M0%+289%28%24.6×42.8%+14.3%
Braskem S.A. Sponsored ADR Pfd BAKUnited States$421M-82%-1%1%1.6×n/an/a
FuJian Nox Bellcow 300132.SZChina$422M-32%+18%7%16.5×-4.3%-10.5%
Koatsu Gas Kogyo 4097.TJapan$423M+10%+4%7%n/a-9.6%+5.1%
Nantong Jiangtian Chemical 300927.SZChina$425M-32%+51%5%n/a16.3%+29.0%
Guangdong Tianan New Material 603725.SSChina$425M-10%-12%2%n/a19.4%+29.0%
Shanghai Huide Science & Technology 603192.SSChina$426M-22%+10%3%n/a9.0%+10.5%
Tatva Chintan Pharma Chem TATVA.NSIndia$412M+29%+50%13%49.8×n/an/a
Guangdong Delian 002666.SZChina$410M-30%+3%0%n/an/an/a
Oriental Union Chemical 1710.TWTaiwan$409M+41%+1%0%16.1×n/an/a
Baotou Dongbao Bio-Tech 300239.SZChina$408M-14%+7%7%n/an/an/a
UPC Technology 1313.TWTaiwan$435M+9%-1%0%n/a38.2%+2.5%
KPIC 006650.KSSouth Korea$405M-40%+11%4%8.9×n/an/a
Zhejiang Haisen Pharmaceutical 001367.SZChina$404M-24%+9%29%n/a-3.9%+13.4%
Zhejiang Jianye Chemical 603948.SSChina$438M-36%-5%12%n/a-4.3%+3.5%
Qingdao Copton Technology 603798.SSChina$401M-43%-7%5%n/a19.9%+0.9%
Shenyang Chemical Industry 000698.SZChina$443M-4%+18%1%n/an/an/a
Changhua Chemical Technology 301518.SZChina$443M-44%+17%-2%n/an/an/a
Hubei Shuanghuan Science and Technology 000707.SZChina$399M-11%-10%-10%n/a56.5%+3.1%
Vishnu Chemicals VISHNU.NSIndia$398M-8%+14%13%20.1×n/an/a

Questions

Which companies are Gevo's closest peers?
The cockpit's peer set: Ellenbarrie Industrial Gases (ELLEN.NS), Braskem S.A. Sponsored ADR Pfd (BAK), FuJian Nox Bellcow (300132.SZ), Koatsu Gas Kogyo (4097.T), Nantong Jiangtian Chemical (300927.SZ), Guangdong Tianan New Material (603725.SS), Shanghai Huide Science & Technology (603192.SS), Tatva Chintan Pharma Chem (TATVA.NS).
Is Gevo expensive compared with its peers?
On forward p/e it trades at 24.8× against a peer median of 16.5×, 2nd most expensive of 8 in its peer set.
How has Gevo stock performed?
Over six months to 18 Nov 2026 the shares returned +3.7% against -18.0% for the median peer; over one year -11.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.